Sharma, Ashish http://orcid.org/0000-0002-8550-9791
Kumar, Nilesh http://orcid.org/0000-0002-7439-2081
Parachuri, Nikulaa
Bandello, Francesco http://orcid.org/0000-0003-3238-9682
Loewenstein, Anat http://orcid.org/0000-0002-7706-1165
Kuppermann, Baruch D.
Article History
Received: 5 January 2024
Revised: 12 February 2024
Accepted: 21 February 2024
First Online: 4 March 2024
Competing interests
: Dr Ashish Sharma: CONSULTANT: for Novartis, Allergan, Bayer and Intas. Dr Francesco Bandello: CONSULTANT: Allergan, Bayer, Boehringer- Ingelheim, FidiaSooft, Hofmann La Roche, Novartis, NTC Pharma, Sifi, Thrombogenics, Zeiss. Dr Anat Loewenstein reports other from Allergan, other from Novartis, other from Roche, other from Notal Vision, other from Forsightslabs, other from Beyeonics, other from Bayer Health Care. Dr Baruch D Kuppermann: CLINICAL RESEARCH: Apellis, Genentech Inc, Boehringer Ingelheim, EyePoint, Ionis, IVERIC Bio, Novartis Pharmaceuticals, Regeneron Pharmaceuticals Inc, RegenXBio; CONSULTANT: Aviceda, Allegro Ophthalmics, Allergan/AbbVie, Bausch+Lomb, Boehringer Ingelheim, Clearside, Coherus, EyeBio, Eyedaptic, EyePoint, Genentech Inc, Glaukos Corporation, InflammX Therapeutics, IVERIC Bio, jCyte, Mobius, Neurotech Pharmaceuticals, Novartis Pharmaceuticals, Ocular Therapeutix, Outlook Therapeutics, Regeneron Pharmaceuticals Inc, ReVana Therapeutics, Ripple Therapeutics, Stealth Biotherapeutics, TechImmune, Theravance Biopharma, Visgenx. Dr Nilesh Kumar: None. Dr Nikulaa Parachuri: None.